GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Sirio Pharma Co Ltd (SZSE:300791) » Definitions » EBIT

Sirio Pharma Co (SZSE:300791) EBIT : ¥404 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Sirio Pharma Co EBIT?

Sirio Pharma Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥101 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥404 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sirio Pharma Co's annualized ROC % for the quarter that ended in Sep. 2024 was 10.48%. Sirio Pharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 15.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sirio Pharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 6.44%.


Sirio Pharma Co EBIT Historical Data

The historical data trend for Sirio Pharma Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirio Pharma Co EBIT Chart

Sirio Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 170.70 313.77 294.34 293.15 335.11

Sirio Pharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.96 88.38 87.12 127.02 101.20

Competitive Comparison of Sirio Pharma Co's EBIT

For the Packaged Foods subindustry, Sirio Pharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sirio Pharma Co's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Sirio Pharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sirio Pharma Co's EV-to-EBIT falls into.


;
;

Sirio Pharma Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥404 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sirio Pharma Co  (SZSE:300791) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sirio Pharma Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=404.924 * ( 1 - -4.13% )/( (3990.576 + 4053.942)/ 2 )
=421.6473612/4022.259
=10.48 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5165.471 - 589.368 - ( 585.527 - max(0, 751.364 - 1869.316+585.527))
=3990.576

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5283.993 - 592.653 - ( 637.398 - max(0, 751.688 - 1963.645+637.398))
=4053.942

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sirio Pharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=404.8/( ( (1908.983 + max(619.428, 0)) + (1911.011 + max(651.971, 0)) )/ 2 )
=404.8/( ( 2528.411 + 2562.982 )/ 2 )
=404.8/2545.6965
=15.90 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(664.432 + 545.493 + 38.533) - (589.368 + 0 + 39.662)
=619.428

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(694.782 + 539.067 + 54.008) - (592.653 + 0 + 43.233)
=651.971

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sirio Pharma Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=403.719/6270.596
=6.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sirio Pharma Co EBIT Related Terms

Thank you for viewing the detailed overview of Sirio Pharma Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sirio Pharma Co Business Description

Traded in Other Exchanges
N/A
Address
No. 83, Taishan Road, Guangdong Province, Shantou, CHN, 515057
Sirio Pharma Co Ltd is engaged in the research and development, production, sales and technical services of nutrition and health food, food production, sales, import and export of goods.
Executives
Chen Qiong Directors, executives
Yao Zhuang Min Directors, executives
Zheng Li Qun Directors, executives
Yang Rui Directors, executives

Sirio Pharma Co Headlines

No Headlines